SIGILON THERAPEUTICS, INC.
Sigilon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of cancer. The company's lead product candidate, SIG-002, is a first-in-class, small molecule inhibitor of the protein kinase AKT1 that is currently in Phase 1 clinical trials for the treatment of advanced solid tumors. Sigilon Therapeutics is also developing a pipeline of other potential therapies for the treatment of cancer.
Disclaimer : All logos and trademarks on this website are the property of their respective owners. The information on this website is not a medical or investment related advice. The information about the company might not reflect the most current or accurate information. Please refer to the company's respective website for the most accurate information.